Audit: QRS - p-Anisic Acid for Health & Longevity

Audit conducted on 24/08/2026 10:24 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	86
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every span traces to ER text: protocol cells to ER Therapeutic Protocol, time cells to ER Practical Considerations, gates to ER Key Interactions & Contraindications, tiers to the ER benefit/risk headings, table to the ER biomarker table.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No timeline established”, “no oral regimen has been studied in people”, “No circadian data exist” all carry the ER’s hedges verbatim.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	“Pregnancy and lactation” stays in the Contraindications gate, matching the ER’s avoid-list; no hedge is dropped or added.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	No item from ER Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates or the risk card.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, no NCT IDs, no author names. Drug names (aspirin, tretinoin, hydrocortisone, hydroquinone, aniracetam, phenoxyethanol) are all present in the ER interaction bullets.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Same restrained, evidence-boundary framing as the ER conclusion.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantities and thresholds are given plainly; the sheet states what is and is not known without discouraging language.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Descriptive throughout (“conventionally applied”, “Skin reassessed at 1 week and 4 weeks”).
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a reader; content is stated as observed practice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “should”, “recommended”, or “advised” in the populated spans.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to biomarker names required by the Monitoring table and threshold values required by the gates.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are reduced to bare facts; explanations and citations are stripped.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no “you”/”your” in the rendered content.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional biomarker targets (fasting insulin 2–5 µIU/mL, hs-CRP below 0.5 mg/L) address exactly this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-daily topical, standardized monthly photographs, and a specialty urinary metabolite assay assume that willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Formulation-level detail and functional ranges are not general-population content.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance frames the compound as a formulation ingredient with no demonstrated human health effect, which is the decision-relevant signal for an optimizer.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear; the header uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Allergic contact dermatitis”, “estimated glomerular filtration rate”, “leave-on or rinse-off product” — consistently formal register carried from the ER.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	A structural diff against the blank template shows zero differences outside the variable spans; all fixed headings and tier labels are byte-identical.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 fixed template spans are present, plus the repeatable patterns expanded correctly to marker_1..7_name/target/why and qualitative_item_1..5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The template/QRS diff shows no modification to CSS, structure, the website= spans, the footer disclaimer, or any non-variable markup.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No QRS section maps to an empty ER section under this rule; the empty benefit/risk tiers and the unused third time set are governed by the more specific items 12.5, 13.5 and 11.3.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1/2/3_label reproduce the ER bold labels “Standard use is formulation-level, not therapeutic”, “Single versus split exposure” and “Time of day” verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol labels are verbatim; the two time labels (“Preservative effect”, “Pigmentation effect”) are taken from the ER’s own wording in the Time to effect bullet (“As a preservative the effect is immediate”, “For any pigmentation effect”).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters anywhere in the file; tiers are marked by bold text labels and CSS colour only.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed rather than transcribed: tier items are collapsed to semicolon-separated headings, gate items to bare facts, and the Monitoring “Context/Notes” column is dropped entirely.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; the comment opens immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment and not duplicated in the header or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, and it contains a colon that requires it.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: p_anisic_acid_2026-0824-0825_Opus_ER.md, matching the ER on disk.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0824-1016.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, context-window qualifier correctly omitted.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: p_anisic_acid_2026-0824-0825_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All nine keys carry trimmed, correctly quoted values.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “p-Anisic Acid for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “p-Anisic Acid for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/24/2026”, matching qrs_creation_date 2026-0824-1016.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; no alternate-names line despite the ER carrying one.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three conclusion paragraphs — what it is, the lopsided evidence, and the closing verdict — into one passage.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Three-route framing and “slows the growth of molds and bacteria in acidic formulas” from the conclusion’s first paragraph; “Laboratory work is consistent” and the absence of any measured human health outcome from the second; the closing sentence is near-verbatim ER.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “absorption and disposal” replaces the ER’s pharmacokinetic register.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No study is named.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items come from the “Populations who should avoid p-Anisic Acid” list in that ER section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-list entries are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 556–560, five separate <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationales stripped throughout: “for whom leave-on cosmetic exposure is uncharacterized”, “since the conjugate is cleared renally” and “where no safety outcome data exist at any exposure level” are all removed.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“graded ++ or stronger”, “under 12 months”, “more than 10% of body surface area”, “Stage 4 or worse” and the eGFR-below-30 threshold are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER does name such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map one-to-one onto the seven bulleted interactions in that ER section, in the same order.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	No overlap with the five contraindication entries.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 568–574, seven separate <li> elements.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Caution —”/”Monitor —” clause is stripped, including the Ogiso citation attached to the aniracetam bullet.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All six example-drug parentheticals are retained in full; only the non-qualifying definitional glosses are trimmed.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies seven such interactions and the section is populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells come from the ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Concentration, application frequency and timing — the three executable axes among twelve ER bullets, the remainder being background (competing approaches, popularizers, genetics, sex, age).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies at least three distinct actionable aspects and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content; e.g. “0.1–0.5% free acid” and “Or the molar equivalent as sodium anisate, in a finished leave-on or rinse-off product” from the ER’s first protocol bullet.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s Time to effect bullet contains exactly two aspects — preservative and pigmentation — and both are carried; no further time-to-effect aspect exists in the ER to occupy the third set.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Preservative effect precedes pigmentation, matching the ER’s ordering of the corresponding Speculative benefits.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	Lines 521, 524 and 527: time_3_label/value/sub are empty and carry style="display: none".
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“Immediate / Verified by product challenge testing, not by the user” and “No timeline established / Because no human study has measured one” are both near-verbatim ER.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	The five listed items are the ER’s five Speculative benefit headings.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 537–546.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to bare headings; the 0.60 mM tyrosinase figure, the rat-study details and all PMID citations are dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in the benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER’s High and Medium tiers state that no benefit reaches them and its Low tier is empty; all three spans are emptied and set to display: none rather than carrying the ER’s “No benefit reaches High” text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Two Low and six Speculative items match the ER’s headings in that section exactly.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 586–601.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to bare headings; the ER’s “Magnitude:” lines (0.0% sensitization in 21,325 patients; CV above 0.3 in 183 adults) are correctly omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in the risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high and risks_medium are emptied and set to display: none, matching the ER’s “No risk reaches High/Medium”.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows reproduce the ER Monitoring Protocol & Defining Success biomarker table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER rows present — fasting glucose, HbA1c, fasting insulin, hs-CRP, eGFR, ALT and urinary 4-methoxyhippuric acid — with targets and rationales verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 699: carries the ER’s 1-week / 4-week / 3–6-month skin schedule and the 12-week / 6–12-month glucose schedule.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the ER’s “Qualitative markers worth tracking” list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers are present and reproduced verbatim, none dropped.

Issues 24/08/2026 10:24

Pass rate 100.00%. No issues found.